C4 therapeutics reports second quarter 2022 financial results and recent business highlights

– cft7455, a novel ikzf1/3 degrader, advancing through dose escalation portion of phase 1/2 clinical trial –
CCCC Ratings Summary
CCCC Quant Ranking